Cleveland Clinic is pleased to present the first symposium on Beta Cell Therapy for the Management of Diabetes. The symposium is designed to improve the management of patient care and promote collaboration between multidisciplinary providers with enhancement of outcome metrics at the community, national and international level.

This unique day and a half symposium, led by Cleveland Clinic Transplant Center director, Kareem Abu-Elmagd, MD, will focus on in-depth pathophysiology of diabetes and biology of beta cells. It also features significant advances in the field of basic and clinical science related to treatment of diabetes with beta cell and solid pancreas transplant. It will review prevention, as well newest technologies available for type 1 diabetes including technological advancements from both the biologic and device technology fields, discussing challenges, opportunities and future directions.

By providing relevant discussions of the most current evidence, this educational offering strives to help practitioners acquire knowledge and skills regarding new data and technology which, in turn, can be translated directly to their clinical practice. Our goal is to improve the quality of patient care and enhance the level of information available to the physicians and other providers involved in diagnosis and treatment.

Cleveland Clinic faculty and visiting experts from general surgery, endocrinology, biology, and transplantation will be present to share their expert opinions.

Key Topics

• Pathophysiology of diabetes
• Bio physiology of beta cells
• Artificial Pancreas
• Auto-Islet transplantation
• Allo-Islet transplantation
• Solid pancreas transplantation

Improve Your Knowledge To:

• Review the pathophysiology of type 1 and type 2 diabetes
• Recognize recent advances in beta cell therapy for the different types of diabetes
• Identify clinical testing end-points and long lasting immuno-protection methodology for encapsulation of islet cells.
• Address the current short and long term outcome after pancreas and islet cell transplantation utilizing the largest clinical database and multi-center national trials. Prediction and early diagnosis of islet cell rejection.
• Describe the pathogenesis and underlying mechanisms of islet cell dysfunction in diabetes
• Identify current preventive modalities for type 1 diabetes. Indicate recent biotechnical advances in the treatment of diabetes
• Identify clinical testing end-points and long lasting immuno-protection methodology for encapsulation of islet cells. Recent advances in maximizing viability and durability of islet cells
• Discuss challenges in bioengineering of beta cells and what constitutes a ‘functional beta cell’.
• Highlight the current methodology for isolation and purification of beta cells
• Report the current status of the long term therapeutic efficacy of solid pancreas transplant alone or combined with kidney.
• Identify new modalities for the immunosuppression management of solid pancreas transplantation.

Who Should Attend?

Surgeons, Endocrinologists, Biologists, Nurses, Allied Health Professionals in the specialty area, and other healthcare professionals.

For more information or to register, visit www.ccfcme.org/AttendBetaCell